These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15177192

  • 1. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?
    Lambrechts D, Storkebaum E, Carmeliet P.
    Trends Mol Med; 2004 Jun; 10(6):275-82. PubMed ID: 15177192
    [Abstract] [Full Text] [Related]

  • 2. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
    Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P.
    Nat Genet; 2003 Aug; 34(4):383-94. PubMed ID: 12847526
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
    Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W.
    Muscle Nerve; 2006 Oct; 34(4):391-405. PubMed ID: 16856151
    [Abstract] [Full Text] [Related]

  • 4. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?
    Iłzecka J.
    Curr Opin Investig Drugs; 2006 Jan; 7(1):54-9. PubMed ID: 16425672
    [Abstract] [Full Text] [Related]

  • 5. A new piece of the ALS puzzle.
    Cleveland JL.
    Nat Genet; 2003 Aug; 34(4):357-8. PubMed ID: 12923539
    [No Abstract] [Full Text] [Related]

  • 6. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype.
    Lambrechts D, Poesen K, Fernández-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW, Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Andersen PM, Van den Berg LH, Thijs V, Siddique T, Robberecht W, Carmeliet P.
    J Med Genet; 2009 Dec; 46(12):840-6. PubMed ID: 18413368
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor attenuates neurodegenerative changes in the NSC-34 motor neuron cell line induced by cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients.
    Kulshreshtha D, Vijayalakshmi K, Alladi PA, Sathyaprabha TN, Nalini A, Raju TR.
    Neurodegener Dis; 2011 Dec; 8(5):322-30. PubMed ID: 21389676
    [Abstract] [Full Text] [Related]

  • 8. Another angiogenic gene linked to amyotrophic lateral sclerosis.
    Lambrechts D, Lafuste P, Carmeliet P, Conway EM.
    Trends Mol Med; 2006 Aug; 12(8):345-7. PubMed ID: 16843725
    [Abstract] [Full Text] [Related]

  • 9. The role of AMPA receptors and VEGF in ALS.
    Van Damme P.
    Verh K Acad Geneeskd Belg; 2009 Aug; 71(4):241-50. PubMed ID: 20084835
    [Abstract] [Full Text] [Related]

  • 10. VEGF and ALS.
    Sathasivam S.
    Neurosci Res; 2008 Oct; 62(2):71-7. PubMed ID: 18656504
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice.
    Zheng C, Sköld MK, Li J, Nennesmo I, Fadeel B, Henter JI.
    Biochem Biophys Res Commun; 2007 Nov 30; 363(4):989-93. PubMed ID: 17923114
    [Abstract] [Full Text] [Related]

  • 14. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons.
    Subramanian V, Crabtree B, Acharya KR.
    Hum Mol Genet; 2008 Jan 01; 17(1):130-49. PubMed ID: 17916583
    [Abstract] [Full Text] [Related]

  • 15. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.
    Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, Nardini M, Donadoni C, Salani S, Fortunato F, Strazzer S, Bresolin N, Comi GP.
    Brain; 2007 May 01; 130(Pt 5):1289-305. PubMed ID: 17439986
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.
    Iłzecka J.
    Clin Neurol Neurosurg; 2004 Sep 01; 106(4):289-93. PubMed ID: 15297002
    [Abstract] [Full Text] [Related]

  • 18. Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC.
    Wilson JM, Petrik MS, Moghadasian MH, Shaw CA.
    Can J Physiol Pharmacol; 2005 Feb 01; 83(2):131-41. PubMed ID: 15791286
    [Abstract] [Full Text] [Related]

  • 19. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS).
    Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, Taylor JA.
    J Neurogenet; 2004 Feb 01; 18(2):429-34. PubMed ID: 15763997
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.